1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
3
|
Crea F, Danesi R and Farrar WL: Cancer
stem cell epigenetics and chemoresistance. Epigenomics. 1:63–79.
2009. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Bohl SR, Pircher A and Hilbe W: Cancer
stem cells: Characteristics and their potential role for new
therapeutic strategies. Onkologie. 34:269–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
6
|
Watanabe Y, Yoshimura K, Yoshikawa K,
Tsunedomi R, Shindo Y, Matsukuma S, Maeda N, Kanekiyo S, Suzuki N,
Kuramasu A, et al: A stem cell medium containing neural stimulating
factor induces a pancreatic cancer stem-like cell-enriched
population. Int J Oncol. 45:1857–1866. 2014.PubMed/NCBI
|
7
|
McCubrey JA, Steelman LS, Abrams SL,
Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti
G, Stivala F, et al: Targeting the cancer initiating cell: The
ultimate target for cancer therapy. Curr Pharm Des. 18:1784–1795.
2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Qi H, Sun B, Zhao X, Du J, Gu Q, Liu Y,
Cheng R and Dong X: Wnt5a promotes vasculogenic mimicry and
epithelial-mesenchymal transition via protein kinase Cα in
epithelial ovarian cancer. Oncol Rep. 32:771–779. 2014.PubMed/NCBI
|
10
|
Wang WJ, Wu MY, Shen M, Zhi Q, Liu ZY,
Gong FR, Tao M and Li W: Cantharidin and norcantharidin impair
stemness of pancreatic cancer cells by repressing the β-catenin
pathway and strengthen the cytotoxicity of gemcitabine and
erlotinib. Int J Oncol. 47:1912–1922. 2015.PubMed/NCBI
|
11
|
Liu W, Dong X, Mai M, Seelan RS, Taniguchi
K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C,
et al: Mutations in AXIN2 cause colorectal cancer with defective
mismatch repair by activating beta-catenin/TCF signalling. Nat
Genet. 26:146–147. 2000. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Miyoshi Y, Nagase H, Ando H, Horii A,
Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T and Nakamura Y:
Somatic mutations of the APC gene in colorectal tumors: Mutation
cluster region in the APC gene. Hum Mol Genet. 1:229–233. 1992.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
|
14
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Segditsas S and Tomlinson I: Colorectal
cancer and genetic alterations in the Wnt pathway. Oncogene.
25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Tian XH, Hou WJ, Fang Y, Fan J, Tong H,
Bai SL, Chen Q, Xu H and Li Y: XAV939, a tankyrase 1 inhibitior,
promotes cell apoptosis in neuroblastoma cell lines by inhibiting
Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 32:1002013.
View Article : Google Scholar
|
17
|
Huang SM, Mishina YM, Liu S, Cheung A,
Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner
S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt
signalling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan
CW, Wei S, Hao W, Kilgore J, Williams NS, et al: Small
molecule-mediated disruption of Wnt-dependent signaling in tissue
regeneration and cancer. Nat Chem Biol. 5:100–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Takahashi-Yanaga F and Kahn M: Targeting
Wnt signaling: Can we safely eradicate cancer stem cells? Clin
Cancer Res. 16:3153–3162. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
McCubrey JA, Steelman LS, Abrams SL,
Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti
G, Stivala F, et al: Targeting the cancer initiating cell: The
ultimate target for cancer therapy. Curr Pharm Des. 18:1784–1795.
2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ying J, Tsujii M, Kondo J, Hayashi Y, Kato
M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, et al: The
effectiveness of an anti-human IL-6 receptor monoclonal antibody
combined with chemotherapy to target colon cancer stem-like cells.
Int J Oncol. 46:1551–1559. 2015.PubMed/NCBI
|
22
|
Wang B, Zou Q, Sun M, Chen J, Wang T, Bai
Y, Chen Z, Chen B and Zhou M: Reversion of trichostatin A
resistance via inhibition of the Wnt signaling pathway in human
pancreatic cancer cells. Oncol Rep. 32:2015–2022. 2014.PubMed/NCBI
|
23
|
Moon RT, Bowerman B, Boutros M and
Perrimon N: The promise and perils of Wnt signaling through
beta-catenin. Science. 296:1644–1646. 2002. View Article : Google Scholar : PubMed/NCBI
|
24
|
Renna C, Salaroli R, Cocchi C and Cenacchi
G: XAV939-mediated ARTD activity inhibition in human MB cell lines.
PLoS One. 10:e01241492015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bao R, Christova T, Song S, Angers S, Yan
X and Attisano L: Inhibition of tankyrases induces Axin
stabilization and blocks Wnt signalling in breast cancer cells.
PLoS One. 7:e486702012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Li J, Yang S, Su N, Wang Y, Yu J, Qiu H
and He X: Overexpression of long non-coding RNA HOTAIR leads to
chemoresistance by activating the Wnt/β-catenin pathway in human
ovarian cancer. Tumour Biol. Sep 4–2015.(Epub ahead of print).
|
27
|
Botting GM, Rastogi I, Chhabra G, Nlend M
and Puri N: Mechanism of resistance and novel targets mediating
resistance to EGFR and c-Met tyrosine kinase inhibitors in
non-small cell lung cancer. PLoS One. 10:e01361552015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Ma L, Wang X, Jia T, Wei W, Chua MS and So
S: Tankyrase inhibitors attenuate WNT/β-catenin signaling and
inhibit growth of hepatocellular carcinoma cells. Oncotarget.
6:25390–25401. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Vakiani E, Janakiraman M, Shen R, Sinha R,
Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, et al:
Comparative genomic analysis of primary versus metastatic
colorectal carcinomas. J Clin Oncol. 30:2956–2962. 2012. View Article : Google Scholar : PubMed/NCBI
|
30
|
Schneider M, Huber J, Hadaschik B, Siegers
GM, Fiebig HH and Schüler J: Characterization of colon cancer
cells: A functional approach characterizing CD133 as a potential
stem cell marker. BMC Cancer. 12:962012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yang ZL, Zheng Q, Yan J, Pan Y and Wang
ZG: Upregulated CD133 expression in tumorigenesis of colon cancer
cells. World J Gastroenterol. 17:932–937. 2011. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wang BB, Li ZJ, Zhang FF, Hou HT, Yu JK
and Li F: Clinical significance of stem cell marker CD133
expression in colorectal cancer. Histol Histopathol. Oct
7–2015.(Epub ahead of print).
|
33
|
Vogler T, Kriegl L, Horst D, Engel J,
Sagebiel S, Schäffauer AJ, Kirchner T and Jung A: The expression
pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent
prognostic marker for low survival in colorectal tumors. Exp Mol
Pathol. 92:111–117. 2012. View Article : Google Scholar
|
34
|
Kanwar SS, Yu Y, Nautiyal J, Patel BB and
Majumdar AP: The Wnt/beta-catenin pathway regulates growth and
maintenance of colonospheres. Mol Cancer. 9:2122010. View Article : Google Scholar : PubMed/NCBI
|
35
|
Imrich S, Hachmeister M and Gires O: EpCAM
and its potential role in tumor-initiating cells. Cell Adhes Migr.
6:30–38. 2012. View Article : Google Scholar
|
36
|
Nakanishi Y, Seno H, Fukuoka A, Ueo T,
Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, et
al: Dclk1 distinguishes between tumor and normal stem cells in the
intestine. Nat Genet. 45:98–103. 2013. View
Article : Google Scholar
|
37
|
Geng M, Yin YC, Cao YC, Fu ZJ, Wang XY and
Tai YH: Anti-tumor effects of chemotherapeutic drugs on human
gastric cancer cells in vitro and the relationship with expression
of hTERT mRNA. Zhonghua Zhong Liu Za Zhi. 29:838–841. 2007.(In
Chinese).
|
38
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Wang XH, Sun X, Meng XW, Lü ZW, Liu MN and
Pei FH: The role and significance of Wnt/beta-catenin signaling
pathway regulating the signaling molecules in hepatocellular
carcinoma. Zhonghua Gan Zang Bing Za Zhi. 18:672–675. 2010.(In
Chinese). PubMed/NCBI
|
40
|
Femia AP, Dolara P, Salvadori M and
Caderni G: Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem
cell markers, in the early phases of 1,2-dimethylhydrazine-induced
rat colon carcinogenesis: Correlation with nuclear β-catenin. BMC
Cancer. 13:482013. View Article : Google Scholar
|
41
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Wang H, Hao J and Hong CC: Cardiac
induction of embryonic stem cells by a small molecule inhibitor of
Wnt/β-catenin signaling. ACS Chem Biol. 6:192–197. 2011. View Article : Google Scholar :
|